Abstract：
UNASSIGNED: The mitogen-activated protein kinase (MAPK) family consist of p38 MAP kinases, c-Jun N-terminal kinases (JNKs) and extracellular signal-regulated kinases (ERKs). They are involved in a multitude of diseases, including inflammatory, autoimmune, neurodegenerative, and metabolic diseases as well as cancer. In recent years, further developments in the field of MAPK-inhibitors have been reported, including an isoform or downstream target selective inhibition of MAPKs as well as target protein degradation approaches.
UNASSIGNED: This review summarizes newly patented MAPK-inhibitors that were claimed between 2018 and early 2023. Presented are the patents as well as their corresponding publications, the storyline of development, and clinical trials involving these compounds. This article elaborates a total of 27 patents, which were identified using established search engines.
UNASSIGNED: Although industrial research on MAPK-inhibitors has been ongoing for more than 20 years, novel clinical trials of MAPK-inhibitors as potential drug candidates are still being conducted in the period under review. Recently reported inhibitors show an excellent selectivity profile and are even achieving selectivity between closely related isoforms. This progression offers the possibility to eliminate unwanted side effects and may finally lead to the approval of the first MAPK-inhibitor.
UNASSIGNED: This review summarizes newly patented MAPK-inhibitors that were claimed between 2018 and early 2023. Presented are the patents as well as their corresponding publications, the storyline of development, and clinical trials involving these compounds. This article elaborates a total of 27 patents, which were identified using established search engines.
UNASSIGNED: Although industrial research on MAPK-inhibitors has been ongoing for more than 20 years, novel clinical trials of MAPK-inhibitors as potential drug candidates are still being conducted in the period under review. Recently reported inhibitors show an excellent selectivity profile and are even achieving selectivity between closely related isoforms. This progression offers the possibility to eliminate unwanted side effects and may finally lead to the approval of the first MAPK-inhibitor.
摘要：
■丝裂原活化蛋白激酶（MAPK）家族由p38MAP激酶组成，c-JunN末端激酶(JNKs)和细胞外信号调节激酶(ERKs)。他们参与了多种疾病，包括炎症，自身免疫，神经退行性疾病，代谢性疾病和癌症。近年来,已经报道了MAPK抑制剂领域的进一步发展，包括MAPKs的同工型或下游靶选择性抑制以及靶蛋白降解方法。
■这篇综述总结了2018年至2023年初声称的新专利MAPK抑制剂。提出的是专利及其相应的出版物，发展的故事情节，和涉及这些化合物的临床试验。本文阐述了共27项专利,使用已建立的搜索引擎识别。
■尽管对MAPK抑制剂的工业研究已经进行了20多年，在本报告所述期间,MAPK抑制剂作为潜在候选药物的新型临床试验仍在进行.最近报道的抑制剂显示出优异的选择性曲线,并且甚至在密切相关的同种型之间实现选择性。这种进展提供了消除不需要的副作用的可能性,并且可能最终导致第一种MAPK抑制剂的批准。
■这篇综述总结了2018年至2023年初声称的新专利MAPK抑制剂。提出的是专利及其相应的出版物，发展的故事情节，和涉及这些化合物的临床试验。本文阐述了共27项专利,使用已建立的搜索引擎识别。
■尽管对MAPK抑制剂的工业研究已经进行了20多年，在本报告所述期间,MAPK抑制剂作为潜在候选药物的新型临床试验仍在进行.最近报道的抑制剂显示出优异的选择性曲线,并且甚至在密切相关的同种型之间实现选择性。这种进展提供了消除不需要的副作用的可能性,并且可能最终导致第一种MAPK抑制剂的批准。
